Bonouvrié LA, Becher JG, Vles JS, Boeschoten K, Soudant D, de Groot V, van Ouwerkerk WJ, Strijers RL, Foncke E, Geytenbeek J, va - November 8, 2013
Background: Dystonic cerebral palsy is primarily caused by damage to the basal ganglia and central cortex. The daily care of these patients can be difficult due to dystonic movements. Intrathecal baclofen treatment is a potential treatment option for dystonia and has become common practice. Despite this widespread adoption, high quality evidence on the effects of intrathecal baclofen treatment on daily activities is lacking and prospective data are needed to judge the usefulness and indications for dystonic cerebral palsy.